Latest Sipuleucel-T Stories
Researchers say that the cost of treating cancer is spiraling out of control and becoming unaffordable in many developed countries.
BETHESDA, Md., Aug.
SEATTLE, Aug. 5, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the Canaccord Genuity Growth Conference in Boston, MA on August 10 at 5:00 PM EDT.
SEATTLE, Aug. 3, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the second quarter ended June 30, 2011. Net revenue for the quarter ended June 30, 2011 was $49.6 million compared to $2.8 million for the quarter ended June 30, 2010.
NEW YORK, July 18, 2011 /PRNewswire/ -- Just one year after the FDA approved Provenge, an immunotherapy for treating advanced prostate cancer, Medicare announced that they will continue to pay in full for Provenge when used in accordance with label indications.
SEATTLE, July 8, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Wednesday, August 3, 2011 at 4:30 p.m. ET to review the second quarter 2011 financial results.
SEATTLE, June 30, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced significant milestones that support broad availability for on-label use of PROVENGEÂ® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
- a meat pie that is usually eaten at Christmas in Quebec